Hamilton Thorne Ltd. announces share consolidation in connection with
Qualifying Transaction

    
    /THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR
    DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED
    STATES./

    TSX VENTURE: TTO.P
    

TORONTO , Nov. 2 /CNW/ - Hamilton Thorne Ltd. (TSX VENTURE: TTO.P) (the "Company"), formerly Calotto Capital Inc., a leading provider of advanced laser systems and instruments for the stem cell research and fertility clinic markets, announced that in connection with its previously announced Qualifying Transaction, the Company completed a consolidation of its issued and outstanding shares on October 26, 2009 . Before the consolidation, there were 22,211,925 Common Shares issued and outstanding. The Common Shares were then consolidated on the basis of one Common Share for every 7.712255 Common Shares then issued and outstanding.

Concurrently with the Qualifying Transaction, Hamilton Thorne completed financings relating to a Private Placement and debt conversion in the gross amount of $2,200,000 through the issuance of 18,098.655 units in the capital of Hamilton Thorne ("Units"). Each Unit consisted of one share of common stock and one common share purchase warrant of Hamilton Thorne.

Upon the issuance of the Final Exchange Bulletin approving the Qualifying Transaction, the Company's share capital will be comprised of the following:

    
    -   24,415,157 common shares issued outstanding,
    -   5,500,005 common share purchase warrants outstanding, and
    -   3,719,684 common share stock options reserved for issuance under the
        2009 Stock Option Plan.
    

About Hamilton Thorne Ltd.

Hamilton Thorne's advanced laser systems and instruments are rapidly emerging as the dominant products to facilitate precise procedures in the stem cell research and fertility clinic markets. Hamilton Thorne's lead products, the ZILOS-tk and XYClone laser systems, attach to standard inverted microscopes and operate as robotic micro-surgeons, significantly reducing time and increasing efficiency in key in-vitro fertilization, stem cell, embryo, reproductive toxicology and living cell procedures.

Hamilton Thorne's growing customer base includes pharmaceutical companies, biotechnology companies, fertility clinics, university research centers and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard University, MIT, Yale, DuPont, Monsanto, Charles River Labs, Jackson Labs , Merck, Novartis, Pfizer, Oxford University and Cambridge.

    
    NEITHER THE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM
    IS DEFINED IN THE POLICIES OF THE EXCHANGE) ACCEPTS RESPONSIBILITY FOR
    THE ADEQUACY OR ACCURACY OF THIS RELEASE.
    

CERTAIN INFORMATION IN THIS PRESS RELEASE MAY CONTAIN FORWARD-LOOKING STATEMENTS. THIS INFORMATION IS BASED ON CURRENT EXPECTATIONS THAT ARE SUBJECT TO SIGNIFICANT RISKS AND UNCERTAINTIES THAT ARE DIFFICULT TO PREDICT. ACTUAL RESULTS MIGHT DIFFER MATERIALLY FROM RESULTS SUGGESTED IN ANY FORWARD-LOOKING STATEMENTS. THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS, OR TO UPDATE THE REASONS WHY ACTUAL RESULTS COULD DIFFER FROM THOSE REFLECTED IN THE FORWARD LOOKING-STATEMENTS UNLESS AND UNTIL REQUIRED BY SECURITIES LAWS APPLICABLE TO THE COMPANY. ADDITIONAL INFORMATION IDENTIFYING RISKS AND UNCERTAINTIES IS CONTAINED IN FILINGS BY THE COMPANY WITH THE CANADIAN SECURITIES REGULATORS, WHICH FILINGS ARE AVAILABLE AT WWW.SEDAR.COM.

THIS IS NOT AN OFFER FOR SALE, OR A SOLICITATION OF AN OFFER TO BUY, IN THE UNITED STATES OR TO ANY "U.S. PERSON," AS SUCH TERM IS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. 1933 ACT") OF ANY EQUITY SHARES OR ANY OTHER SECURITIES OF THE COMPANY OR HAMILTON THORNE.

THE COMMON SHARES AND OTHER SECURITIES OF THE COMPANY TO BE ISSUED PURSUANT TO THE QUALIFYING TRANSACTION TO THE SECURITY HOLDERS OF HAMILTON THORNE HAVE NOT BEEN REGISTERED UNDER THE U.S. 1933 ACT OR THE LAWS OF ANY STATE OF THE UNITED STATES AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES (OR TO A U.S. PERSON) ABSENT REGISTRATION UNDER THE U.S. 1933 ACT AND/OR ANY APPLICABLE STATE LAWS OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. 1933 ACT AND/OR AN APPLICABLE STATE LAWS.

    
    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this news release.
    

For further information: Hamilton Thorne Ltd., David Wolf, President, [phone], [email protected]; Ross Marshall, The Equicom Group, [phone] x238, [email protected]